Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study
Dermatology · 2024
DOI: 10.1159/000535282 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Dermatology, 2024. Verfasst von Emilio Berna-Rico und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Dermatitis, Atopic. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Dupilumab has recently been shown to be effective in children under 6 years of age with atopic dermatitis (AD). Nevertheless, real-life and long-term follow-up data are scarce. We aimed to assess the effectiveness, safety, and long-term outcomes of dupilumab in a daily-practice setting in this age group.
Method
This was a retrospective observational cohort study. Only patients with 16 or more weeks of treatment were included in the analysis. The proportion of patients who achieved ≥75% or 90% reduction from baseline EASI (EASI75 and EASI90, respectively) and the percentage of patients who achieved vIGA 0–1 were analyzed at 4, 16, 48, 72, and 96 weeks (when available). Adverse events were recorded during follow-up.
Results
A total of 19 patients <6 years old with moderate-to-severe AD were included in the cohort, with a median age of 4.7 years (range: 2.6–5.9). The median weeks on dupilumab were 51.3 (IQR: 24.6–79.3). EASI75 was achieved in 11/19 patients (57.9%) at w4, 16/19 (84.2%) at w16, 9/12 (75%) at w48, 6/6 (100%) at w72, and in 2/2 (100%) at week 96. The objective of vIGA 0–1 was reached by 10/19 patients (51.6%) at w4, by 14/19 (73.7%) at w16, by 9/12 (75%) at w48, by 5/6 (83.3%) at w72, and by 2/2 (100%) at w96. Dupilumab was discontinued in 3 patients (15.8%) due to loss of response. One patient developed a paradoxical palmo-plantar eruption. We found no cases of conjunctivitis, facial erythema, or injection-site reactions related to dupilumab.
Conclusions
Dupilumab was effective and safe in our cohort of patients with moderate-to-severe AD under 6 years of age. Response was maintained in the long term in most patients with longer follow-up. Its adverse effect profile was similar to that found in older children and adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Hospital Universitario Ramon y Cajal, IRYCIS, Madrid, Spain.
- Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain.
Zitieren
APA
Berna-Rico, E., Fiz-Benito, E., Busto-Leis, J. M., Servera-Negre, G., de Lucas-Laguna, R., & Feito-Rodriguez, M. (2024). Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study. Dermatology. https://doi.org/10.1159/000535282
Vancouver
Berna-Rico E, Fiz-Benito E, Busto-Leis JM, Servera-Negre G, de Lucas-Laguna R, Feito-Rodriguez M. Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study. Dermatology. 2024. doi:10.1159/000535282
BibTeX
@article{BernaRico2024,
author = {Berna-Rico, Emilio and Fiz-Benito, Esther and Busto-Leis, Jose Manuel and Servera-Negre, Guillermo and de Lucas-Laguna, Raul and Feito-Rodriguez, Marta},
title = {Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study},
journal = {Dermatology},
year = {2024},
doi = {10.1159/000535282}
}
EUVIMED